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INTRODUCTION
The current global overuse and misuse of
antimicrobials requires an urgent international
response. According to the 2014 World Health
Organization (WHO) Antimicrobial Resistance
Global Report on Surveillance, deaths per year
due to antibiotic resistance are reported as high
as 23,000 in the United States, 25,000 in the
European Union, 38,000 in Thailand and
58,000 in India [1]. The WHO developed a
Global Action Plan in May 2015 mandating
member states to produce national strategic
plans to combat antimicrobial resistance by
establishing a global development and
antibiotic stewardship framework [2]. Many
countries have successfully implemented
antimicrobial stewardship programs in the
hospital setting while several limited resource
countries continue to struggle with getting
stewardship programs up and running.
The art of antimicrobial stewardship (AMS) is
an evolving discipline. The articles in this
themed issue aim to provide the reader with
an overview of successful antimicrobial
stewardship programs from 6 different
countries; the United States, United Kingdom,
South Africa, Singapore, Australia, and Italy.
The authors discuss the international role of
pharmacists in AMS. Included in this issue are
two studies from South Africa and Singapore
and four reviews of stewardship efforts with a
description of the pharmacist’s role.
The issue starts with a study by Messina et al.
from South Africa, a resource-limited country.
This prospective multi-center
pharmacist-driven study aimed to improve the
‘‘hangtime’’ of antibiotics defined as the time
elapsed from the written antibiotic order to
actual intravenous administration. Pharmacists
from 33 hospitals evaluated and intervened on
32,985 patients over a 60-week study period and
significantly improved ‘‘hangtime compliance
from 41.2% to 78.4%. The success of this
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initiative by non-infectious disease pharmacists
is partially attributed to the pharmacist project
manager who coordinated and provided
real-time data and feedback to the frontline
pharmacists. The large number of patients and
sustained efforts provides a successful ASP
model for other countries especially those with
limited resources.
The next study by Loo et al. from Singapore
is a 3-year retrospective review evaluating the
impact of ASP and outcomes of hospitalized
patients with skin and skin soft tissue
infections. Pharmacists made over 400
antimicrobial recommendations with an
overall acceptance rate of 66.8%. They
demonstrated that ASP interventions were safe
and reduced duration of therapy, length of stay
and resulted in institutional cost savings. In
contrast to South Africa, the pharmacists were
ID trained and provided a two-stage prospective
audit with immediate and concurrent feedback
to the physicians. Their ASP model could be
applied to a variety of healthcare settings
worldwide.
The third paper by Cairns K et al. provides a
comprehensive review of the role of
pharmacists in antimicrobial stewardship
(AMS) in Australia. The authors describe the
recent incorporation of AMS into mandatory
hospital accreditation standards and the release
of the first national strategy on antimicrobial
resistance. As there is not a ‘‘one-size fits all’’
model for AMS in Australia, they provide two
different examples, one from a general hospital
setting and one with specialized areas.
Trinh T. et al. provides the United States
perspective for the role of AMS initiatives in the
emergency department (ED). With over 142,000
visits to the ED for antibiotic-related adverse
drug reactions, there is clearly a need for AMS.
The authors describe the top three
infection-related ED visits (urinary tract
infections, skin and soft tissue infections and
pneumonia) and provide ED AMS strategies.
Support from ED practitioners is the first critical
step to implement AMS in the ED.
The next paper by Gilchrist et al. describes
AMS experience from the UK antimicrobial
pharmacist perspective. Pharmacists were
thrust into a key role in AMS in 2003 after the
Department of Health infused significant
funding to hospital pharmacies in England to
improve the monitoring and control of
anti-infectives. The authors provide
documentation of the progress made by
pharmacists working collaboratively with
infectious diseases clinicians, microbiologists,
and other healthcare professional helping to
drive the AMS efforts in both primary and
secondary care.
The final paper by Viale P. et al. reviews the
literature on the topic carbapenem resistance in
the setting of extended spectrum
beta-lactamase resistance and the role of AMS.
In addition, they describe the experience from
an Italian University affiliated hospital
multifaceted infection control and AMS
program to reduce carbapenem-resistant
enterobacteriaceae (CRE) bloodstream
infections. The role of both
ceftolozane/tazobactam and ceftazidime/
avibactam under a specific AMS aim is also
described.
We have designed this issue to provide
clinicians with the latest approaches to AMS
from 6 different countries worldwide. Every
prescriber should be an antibiotic steward.
Pharmacists working in collaboration with
physician colleagues have a key role in AMS
and can be instrumental in initiating the
behavior change necessary to bring about
transformation change in antibiotic use. We
are confident that this information will provide
value to the steward and will start a movement
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to work together in the journey to implement
effective AMS globally.
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